Insider Transactions in Q1 2025 at Madrigal Pharmaceuticals, Inc. (MDGL)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 24
2025
|
Carole Huntsman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
347
-3.22%
|
$116,245
$335.24 P/Share
|
|
Jan 24
2025
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
1,584
-2.83%
|
$530,640
$335.24 P/Share
|
|
Jan 24
2025
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
648
-0.14%
|
$217,080
$335.24 P/Share
|
|
Jan 24
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
103
-2.04%
|
$34,505
$335.24 P/Share
|
|
Jan 17
2025
|
Shannon T Kelley General Counsel |
SELL
Open market or private sale
|
Direct |
277
-3.47%
|
$75,621
$273.41 P/Share
|
|
Jan 17
2025
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
1,689
-0.37%
|
$461,097
$273.41 P/Share
|
|
Jan 17
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
442
-8.04%
|
$120,666
$273.41 P/Share
|